公开(公告)号：US09675598B2

公开(公告)日：2017-06-13

申请号：US15225182

申请日：2016-08-01

Applicant: SANOCHEMIA PHARMAZEUTIKA AG

Inventor： Federico Gaeta ,  Klaus Gerdes ,  Stefan Welzig ,  Beate Katz ,  Jan Rothenburger ,  Jozsef Gungl

IPC: C07D211/20 ,  A61K31/4453 ,  C07D295/108 ,  A61K9/00 ,  A61K9/20

CPC classification number: A61K31/4453 ,  A61K9/0053 ,  A61K9/20 ,  C07D295/108 ,  Y10T436/145555

Abstract: The present disclosure relates to tolperisone, or a pharmaceutically acceptable salt or hydrate thereof, with 10 ppm 2-methyl-1-(4-methylphenyl)-propenone (4-MMPPO) or less, methods of producing the same, as well as compositions related thereto. The disclosure further relates to methods of treating a subject with tolperisone under conditions that limit exposure of the subject to tolerable levels of 4-MMPPO.

公开(公告)号：US10265397B2

公开(公告)日：2019-04-23

申请号：US15805491

申请日：2017-11-07

Applicant: Sanochemia Pharmazeutika AG

Inventor： Stefan Welzig ,  Gregor Medinger ,  Beate Kálz ,  József Gungl ,  Klaus Gerdes ,  Werner Frantsits ,  Christina Abrahamsberg

IPC: A61K41/00 ,  A61K47/58 ,  A61K47/60 ,  A61K9/00 ,  A61K9/08 ,  A61K9/19 ,  A61K47/32 ,  A61N5/06

Abstract: Photodynamic therapy of tumors such as bladder tumors includes photosensitizing with a photosensitizer that is a complex or a compound of hypericin and a polymeric complexing agent. The photosensitizer is formed from an alkali salt of hypericin and the polymeric complexing agent. The alkali salt of hypericin is a sodium salt or a potassium salt. The complexing agent is a polyethylene glycol or a poly-N-vinyl amide.

公开(公告)号：US10201609B2

公开(公告)日：2019-02-12

申请号：US15805664

申请日：2017-11-07

Applicant: Sanochemia Pharmazeutika AG

Inventor： Stefan Welzig ,  Gregor Medinger ,  Beate Kälz ,  József Gungl ,  Klaus Gerdes ,  Werner Frantsits ,  Christina Abrahamsberg

IPC: A61K41/00 ,  A61K47/58 ,  A61K47/60 ,  A61K9/00 ,  A61K9/08 ,  A61K9/19 ,  A61K47/32 ,  A61N5/06

Abstract: Photodynamic therapy of tumors such as bladder tumors includes photosensitizing with a photosensitizer that is a complex or a compound of hypericin and a polymeric complexing agent. The photosensitizer is formed from an alkali salt of hypericin and the polymeric complexing agent. The alkali salt of hypericin is a sodium salt or a potassium salt. The complexing agent is a polyethylene glycol or a poly-N-vinyl amide.

公开(公告)号：US09629932B2

公开(公告)日：2017-04-25

申请号：US14878573

申请日：2015-10-08

Applicant: Sanochemia Pharmazeutika AG

Inventor： Stefan Welzig ,  Beate Kalz ,  Jozsef Gungl ,  Klaus Gerdes ,  Werner Frantsits ,  Christina Abrahamsberg

IPC: A61K9/00 ,  A61K49/00

CPC classification number: A61K41/00 ,  A61K9/0009 ,  A61K9/08 ,  A61K31/121 ,  A61K36/38 ,  A61K41/0057 ,  A61K47/32 ,  A61K49/0021 ,  A61K49/0054 ,  A61K49/0071 ,  C07C50/00 ,  C07C50/36

Abstract: In the early detection of cancer, in particular bladder cancer, a photodynamic diagnosis uses, as a photosensitizer, a formulation that contains sodium hypericinate that is bonded to polyvinylpyrrolidone or complexed with polyvinylpyrrolidone.

公开(公告)号：US10064961B2

公开(公告)日：2018-09-04

申请号：US15500685

申请日：2015-06-15

Applicant: SANOCHEMIA PHARMAZEUTIKA AG

Inventor： Stefan Welzig ,  Raffael Schuecker ,  Beate Kaelz ,  Jozsef Gungl ,  Klaus Gerdes ,  Roswitha Braunrath

IPC: A61K9/00 ,  A61K49/10 ,  A61K9/08

Abstract: A method for producing a liquid pharmaceutical preparation which contains a complex consisting of DOTA and gadolinium and a base such as L-lysine or meglumine, includes the following steps: a) An aqueous solution containing free DOTA, free gadolinium and a base such as L-lysine or meglumine is produced. b) The yield of free DOTA and free gadolinium is determined in the solution obtained according to step a). c) Free gadolinium and/or free DOTA is added in order to adjust a stoichiometric excess of free DOTA in the solution. d) The complexation is executed at an increased temperature. e) Additional base such as L-lysine or meglumine is added in order to adjust the pH value. f) The final volume of the preparation is adjusted.

公开(公告)号：US09775900B2

公开(公告)日：2017-10-03

申请号：US15469602

申请日：2017-03-27

Applicant: Sanochemia Pharmazeutika AG

Inventor： Stefan Welzig ,  Beate Kälz ,  József Gungl ,  Klaus Gerdes ,  Werner Frantsits ,  Christina Abrahamsberg

IPC: A61K9/00 ,  A61K41/00 ,  A61K31/121 ,  A61K36/38 ,  C07C50/36 ,  C07C50/00

CPC classification number: A61K41/00 ,  A61K9/0009 ,  A61K9/08 ,  A61K31/121 ,  A61K36/38 ,  A61K41/0057 ,  A61K47/32 ,  A61K49/0021 ,  A61K49/0054 ,  A61K49/0071 ,  C07C50/00 ,  C07C50/36

Abstract: In the early detection of cancer, in particular bladder cancer, a photodynamic diagnosis uses, as a photosensitizer, a formulation that contains sodium hypericinate that is bonded to polyvinylpyrrolidone or complexed with polyvinylpyrrolidone.

公开(公告)号：US20160220549A1

公开(公告)日：2016-08-04

申请号：US15068006

申请日：2016-03-11

Applicant: SANOCHEMIA PHARMAZEUTIKA AG

Inventor： Federico Gaeta ,  Klaus Gerdes ,  Stefan Welzig ,  Beate Katz ,  Jan Rothenburger ,  Jozsef Gungl

IPC: A61K31/4453 ,  A61K9/00

CPC classification number: A61K31/4453 ,  A61K9/0053 ,  A61K9/20 ,  C07D295/108 ,  Y10T436/145555

Abstract: The present disclosure relates to methods of administering tolperisone to subjects in need thereof. In certain aspects, the present disclosure relates to methods of administering tolperisone to subjects in need thereof, said methods limiting the exposure of the subject to 4-MMPPO.

Abstract translation: 本公开涉及向有需要的受试者施用甲苯哌酮的方法。 在某些方面，本公开涉及将甲苯哌嗪给予有需要的受试者的方法，所述方法将受试者暴露于4-MMPPO。

公开(公告)号：US10143751B2

公开(公告)日：2018-12-04

申请号：US14878515

申请日：2015-10-08

Applicant: Sanochemia Pharmazeutika AG

Inventor： Stefan Welzig ,  Gregor Medinger ,  Beate Kalz ,  Jozsef Gungl ,  Klaus Gerdes ,  Werner Frantsits ,  Christina Abrahamsberg

IPC: A61K41/00 ,  A61K47/58 ,  A61K47/60 ,  A61K9/00 ,  A61K9/08 ,  A61K9/19 ,  A61K47/32 ,  A61N5/06

Abstract: Photodynamic therapy of tumors such as bladder tumors includes photosensitizing with a photosensitizer that is a complex or a compound of hypericin and a polymeric complexing agent. The photosensitizer is formed from an alkali salt of hypericin and the polymeric complexing agent. The alkali salt of hypericin is a sodium salt or a potassium salt. The complexing agent is a polyethylene glycol or a poly-N-vinyl amide.

公开(公告)号：US09662317B2

公开(公告)日：2017-05-30

申请号：US15068006

申请日：2016-03-11

Applicant: SANOCHEMIA PHARMAZEUTIKA AG

Inventor： Federico Gaeta ,  Klaus Gerdes ,  Stefan Welzig ,  Beate Katz ,  Jan Rothenburger ,  Jozsef Gungl

IPC: C07D211/20 ,  A61K31/4453 ,  C07D295/108 ,  A61K9/00 ,  A61K9/20

CPC classification number: A61K31/4453 ,  A61K9/0053 ,  A61K9/20 ,  C07D295/108 ,  Y10T436/145555

Abstract: The present disclosure relates to methods of administering tolperisone to subjects in need thereof. In certain aspects, the present disclosure relates to methods of administering tolperisone to subjects in need thereof, said methods limiting the exposure of the subject to 4-MMPPO.

公开(公告)号：US20160367540A1

公开(公告)日：2016-12-22

申请号：US15225182

申请日：2016-08-01

Applicant: SANOCHEMIA PHARMAZEUTIKA AG

Inventor： Federico Gaeta ,  Klaus Gerdes ,  Stefan Welzig ,  Beate Katz ,  Jan Rothenburger ,  Jozsef Gungl

IPC: A61K31/4453 ,  A61K9/20

CPC classification number: A61K31/4453 ,  A61K9/0053 ,  A61K9/20 ,  C07D295/108 ,  Y10T436/145555

Abstract: The present disclosure relates to tolperisone, or a pharmaceutically acceptable salt or hydrate thereof, with 10 ppm 2-methyl-1-(4-methylphenyl)-propenone (4-MMPPO) or less, methods of producing the same, as well as compositions related thereto. The disclosure further relates to methods of treating a subject with tolperisone under conditions that limit exposure of the subject to tolerable levels of 4-MMPPO.

Abstract translation: 本公开内容涉及具有10ppm 2-甲基-1-（4-甲基苯基） - 丙烯酮（4-MMPPO）或更少的甲苯哌嗪或其药学上可接受的盐或水合物，其制备方法以及组合物 相关。 本公开进一步涉及在将受试者的暴露限制为可耐受水平的4-MMPPO的条件下用甲苯哌酮治疗受试者的方法。